Published in J Virol on August 06, 2008
Fusing structure and function: a structural view of the herpesvirus entry machinery. Nat Rev Microbiol (2011) 2.86
New viruses for cancer therapy: meeting clinical needs. Nat Rev Microbiol (2013) 1.72
Structure of herpes simplex virus glycoprotein D bound to the human receptor nectin-1. PLoS Pathog (2011) 1.53
Herpes simplex virus gD forms distinct complexes with fusion executors gB and gH/gL in part through the C-terminal profusion domain. J Biol Chem (2009) 1.45
Cross talk among the glycoproteins involved in herpes simplex virus entry and fusion: the interaction between gB and gH/gL does not necessarily require gD. J Virol (2009) 1.26
Inhibition of human tumor growth in mice by an oncolytic herpes simplex virus designed to target solely HER-2-positive cells. Proc Natl Acad Sci U S A (2009) 1.14
Binding of herpes simplex virus glycoprotein D to nectin-1 exploits host cell adhesion. Nat Commun (2011) 1.08
Directing systemic oncolytic viral delivery to tumors via carrier cells. Cytokine Growth Factor Rev (2010) 1.06
A double mutation in glycoprotein gB compensates for ineffective gD-dependent initiation of herpes simplex virus type 1 infection. J Virol (2010) 1.02
Effective treatment of an orthotopic xenograft model of human glioblastoma using an EGFR-retargeted oncolytic herpes simplex virus. Mol Ther (2012) 1.02
Oncolytic viruses: From bench to bedside with a focus on safety. Hum Vaccin Immunother (2015) 1.01
HSV Recombinant Vectors for Gene Therapy. Open Virol J (2010) 0.99
αvβ6- and αvβ8-integrins serve as interchangeable receptors for HSV gH/gL to promote endocytosis and activation of membrane fusion. PLoS Pathog (2013) 0.99
Replication-competent herpes simplex virus retargeted to HER2 as therapy for high-grade glioma. Mol Ther (2012) 0.93
Targeted entry of enveloped viruses: measles and herpes simplex virus I. Curr Opin Virol (2011) 0.90
Preclinical therapy of disseminated HER-2⁺ ovarian and breast carcinomas with a HER-2-retargeted oncolytic herpesvirus. PLoS Pathog (2013) 0.89
Oncolytic herpes simplex virus-based strategies: toward a breakthrough in glioblastoma therapy. Front Microbiol (2014) 0.87
Systemic delivery of HER2-retargeted oncolytic-HSV by mesenchymal stromal cells protects from lung and brain metastases. Oncotarget (2015) 0.83
Bispecific adapter-mediated retargeting of a receptor-restricted HSV-1 vector to CEA-bearing tumor cells. Mol Ther (2010) 0.83
The Engineering of a Novel Ligand in gH Confers to HSV an Expanded Tropism Independent of gD Activation by Its Receptors. PLoS Pathog (2015) 0.82
Induction of conformational changes at the N-terminus of herpes simplex virus glycoprotein D upon binding to HVEM and nectin-1. Virology (2013) 0.81
Epstein-Barr viruses that express a CD21 antibody provide evidence that gp350's functions extend beyond B-cell surface binding. J Virol (2009) 0.80
Displacement of the C terminus of herpes simplex virus gD is sufficient to expose the fusion-activating interfaces on gD. J Virol (2013) 0.80
Retargeting Strategies for Oncolytic Herpes Simplex Viruses. Viruses (2016) 0.80
High scFv-receptor affinity does not enhance the antitumor activity of HER2-retargeted measles virus. Cancer Gene Ther (2014) 0.78
Development of an oncolytic HSV vector fully retargeted specifically to cellular EpCAM for virus entry and cell-to-cell spread. Gene Ther (2016) 0.78
The potential application of a transcriptionally regulated oncolytic herpes simplex virus for human cancer therapy. Br J Cancer (2013) 0.77
Crystal structure of herpes simplex virus 2 gD bound to nectin-1 reveals a conserved mode of receptor recognition. J Virol (2014) 0.77
Insertion of a ligand to HER2 in gB retargets HSV tropism and obviates the need for activation of the other entry glycoproteins. PLoS Pathog (2017) 0.76
Retargeting of herpes simplex virus (HSV) vectors. Curr Opin Virol (2016) 0.76
Oncolytic Virotherapy: A Contest between Apples and Oranges. Mol Ther (2017) 0.75
A Strategy for Cultivation of Retargeted Oncolytic Herpes Simplex Viruses in Non-cancer Cells. J Virol (2017) 0.75
One-step inactivation of chromosomal genes in Escherichia coli K-12 using PCR products. Proc Natl Acad Sci U S A (2000) 96.90
Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science (1987) 49.88
ERBB receptors and cancer: the complexity of targeted inhibitors. Nat Rev Cancer (2005) 16.73
Gene disruption in Escherichia coli: TcR and KmR cassettes with the option of Flp-catalyzed excision of the antibiotic-resistance determinant. Gene (1995) 15.67
Herpes simplex virus-1 entry into cells mediated by a novel member of the TNF/NGF receptor family. Cell (1996) 9.03
Entry of alphaherpesviruses mediated by poliovirus receptor-related protein 1 and poliovirus receptor. Science (1998) 7.89
A novel role for 3-O-sulfated heparan sulfate in herpes simplex virus 1 entry. Cell (1999) 6.82
Cloning and mutagenesis of a herpesvirus genome as an infectious bacterial artificial chromosome. Proc Natl Acad Sci U S A (1997) 5.37
Herpesvirus entry: an update. J Virol (2003) 5.19
Cloning of the human cytomegalovirus (HCMV) genome as an infectious bacterial artificial chromosome in Escherichia coli: a new approach for construction of HCMV mutants. J Virol (1999) 4.84
Herpes simplex virus glycoprotein D bound to the human receptor HveA. Mol Cell (2001) 4.44
Conditionally replicating herpes simplex virus mutant, G207 for the treatment of malignant glioma: results of a phase I trial. Gene Ther (2000) 4.33
Cloning and mutagenesis of the murine gammaherpesvirus 68 genome as an infectious bacterial artificial chromosome. J Virol (2000) 4.09
Construction of large DNA segments in Escherichia coli. Science (1989) 3.94
Engineering targeted viral vectors for gene therapy. Nat Rev Genet (2007) 3.69
Attenuated multi-mutated herpes simplex virus-1 for the treatment of malignant gliomas. Nat Med (1995) 3.37
Nectin and afadin: novel organizers of intercellular junctions. J Cell Sci (2003) 3.19
ErbB receptors: directing key signaling networks throughout life. Annu Rev Pharmacol Toxicol (2004) 3.18
Experimental therapy of human glioma by means of a genetically engineered virus mutant. Science (1991) 3.14
Structure of unliganded HSV gD reveals a mechanism for receptor-mediated activation of virus entry. EMBO J (2005) 2.95
Toxicity evaluation of replication-competent herpes simplex virus (ICP 34.5 null mutant 1716) in patients with recurrent malignant glioma. Gene Ther (2000) 2.94
A phase I study of OncoVEXGM-CSF, a second-generation oncolytic herpes simplex virus expressing granulocyte macrophage colony-stimulating factor. Clin Cancer Res (2006) 2.35
Oncolytic viral therapies - the clinical experience. Oncogene (2005) 2.30
Glycoprotein D or J delivered in trans blocks apoptosis in SK-N-SH cells induced by a herpes simplex virus 1 mutant lacking intact genes expressing both glycoproteins. J Virol (2000) 2.26
HSV1716 injection into the brain adjacent to tumour following surgical resection of high-grade glioma: safety data and long-term survival. Gene Ther (2004) 1.91
The multipartite system that mediates entry of herpes simplex virus into the cell. Rev Med Virol (2007) 1.75
The potential for efficacy of the modified (ICP 34.5(-)) herpes simplex virus HSV1716 following intratumoural injection into human malignant glioma: a proof of principle study. Gene Ther (2002) 1.73
Comparative usage of herpesvirus entry mediator A and nectin-1 by laboratory strains and clinical isolates of herpes simplex virus. Virology (2004) 1.73
Viruses as anticancer drugs. Trends Pharmacol Sci (2007) 1.63
Role of mannose-6-phosphate receptors in herpes simplex virus entry into cells and cell-to-cell transmission. J Virol (1995) 1.58
Phage-displayed antibody libraries of synthetic heavy chain complementarity determining regions. J Mol Biol (2004) 1.53
Oncolytic herpes simplex virus vectors for cancer virotherapy. Cancer Gene Ther (2002) 1.51
Evaluation of genetically engineered herpes simplex viruses as oncolytic agents for human malignant brain tumors. Cancer Res (1997) 1.45
Role for 3-O-sulfated heparan sulfate as the receptor for herpes simplex virus type 1 entry into primary human corneal fibroblasts. J Virol (2006) 1.44
Mutations in herpes simplex virus glycoprotein D that prevent cell entry via nectins and alter cell tropism. Proc Natl Acad Sci U S A (2004) 1.43
Oncolytic adenoviruses - selective retargeting to tumor cells. Oncogene (2005) 1.43
The application of genetically engineered herpes simplex viruses to the treatment of experimental brain tumors. Proc Natl Acad Sci U S A (1996) 1.41
Phase I, open-label, dose-escalating study of a genetically engineered herpes simplex virus, NV1020, in subjects with metastatic colorectal carcinoma to the liver. Hum Gene Ther (2006) 1.39
Potential nectin-1 binding site on herpes simplex virus glycoprotein d. J Virol (2005) 1.39
Engineered herpes simplex virus 1 is dependent on IL13Ralpha 2 receptor for cell entry and independent of glycoprotein D receptor interaction. Proc Natl Acad Sci U S A (2002) 1.39
The murine homolog of human Nectin1delta serves as a species nonspecific mediator for entry of human and animal alpha herpesviruses in a pathway independent of a detectable binding to gD. Proc Natl Acad Sci U S A (2000) 1.38
Expression of the p185 encoded by HER2 oncogene in normal and transformed human tissues. Int J Cancer (1990) 1.36
Attenuated, replication-competent herpes simplex virus type 1 mutant G207: safety evaluation of intracerebral injection in nonhuman primates. J Virol (1999) 1.26
Transcription from the gene encoding the herpesvirus entry receptor nectin-1 (HveC) in nervous tissue of adult mouse. Virology (2001) 1.25
Immunoprevention of HER-2/neu transgenic mammary carcinoma through an interleukin 12-engineered allogeneic cell vaccine. Cancer Res (2004) 1.25
Genetically engineered HSV in the treatment of glioma: a review. Rev Med Virol (2000) 1.24
Construction and properties of a herpes simplex virus 1 designed to enter cells solely via the IL-13alpha2 receptor. Proc Natl Acad Sci U S A (2006) 1.22
Reengineering paramyxovirus tropism. Virology (2004) 1.18
Oncolytic efficacy and enhanced safety of measles virus activated by tumor-secreted matrix metalloproteinases. Cancer Res (2006) 1.12
Crystallization and preliminary diffraction studies of the ectodomain of the envelope glycoprotein D from herpes simplex virus 1 alone and in complex with the ectodomain of the human receptor HveA. Acta Crystallogr D Biol Crystallogr (2002) 1.11
HER2 targeted therapy in breast cancer...beyond Herceptin. Rev Endocr Metab Disord (2007) 1.06
Herpes simplex virus 1 recombinant virions exhibiting the amino terminal fragment of urokinase-type plasminogen activator can enter cells via the cognate receptor. Gene Ther (2006) 1.06
Random mutagenesis of the gene encoding a viral ligand for multiple cell entry receptors to obtain viral mutants altered for receptor usage. Proc Natl Acad Sci U S A (2004) 1.02
A herpes simplex virus recombinant that exhibits a single-chain antibody to HER2/neu enters cells through the mammary tumor receptor, independently of the gD receptors. J Virol (2006) 1.02
Characterization of a recombinant herpes simplex virus 1 designed to enter cells via the IL13Ralpha2 receptor of malignant glioma cells. J Virol (2005) 1.00
Separation of receptor-binding and profusogenic domains of glycoprotein D of herpes simplex virus 1 into distinct interacting proteins. Proc Natl Acad Sci U S A (2007) 0.98
HveC (nectin-1) is expressed at high levels in sensory neurons, but not in motor neurons, of the rat peripheral nervous system. J Neurovirol (2001) 0.95
Expression of HER/erbB family of receptor tyrosine kinases and induction of differentiation by glial growth factor 2 in human rhabdomyosarcoma cells. Int J Cancer (2000) 0.90
Oncolytic HSV-1 for the treatment of brain tumours. Herpes (2006) 0.89
Characterization of soluble glycoprotein D-mediated herpes simplex virus type 1 infection. Virology (2006) 0.87
Friendly fire: redirecting herpes simplex virus-1 for therapeutic applications. Clin Microbiol Infect (2002) 0.80
Host immune system gene targeting by a viral miRNA. Science (2007) 5.10
Memory inflation: continuous accumulation of antiviral CD8+ T cells over time. J Immunol (2003) 3.02
Decoding human cytomegalovirus. Science (2012) 2.98
MCMV glycoprotein gp40 confers virus resistance to CD8+ T cells and NK cells in vivo. Nat Immunol (2002) 2.66
Enforced viral replication activates adaptive immunity and is essential for the control of a cytopathic virus. Nat Immunol (2011) 2.51
Expansion of CD94/NKG2C+ NK cells in response to human cytomegalovirus-infected fibroblasts. Blood (2005) 2.40
Cloning and sequencing of a highly productive, endotheliotropic virus strain derived from human cytomegalovirus TB40/E. J Gen Virol (2008) 2.35
A novel human polyomavirus closely related to the african green monkey-derived lymphotropic polyomavirus. J Virol (2011) 2.03
Complexes between herpes simplex virus glycoproteins gD, gB, and gH detected in cells by complementation of split enhanced green fluorescent protein. J Virol (2007) 1.95
Identification and expression of human cytomegalovirus transcription units coding for two distinct Fcgamma receptor homologs. J Virol (2002) 1.92
The soluble ectodomain of herpes simplex virus gD contains a membrane-proximal pro-fusion domain and suffices to mediate virus entry. Proc Natl Acad Sci U S A (2004) 1.89
The multipartite system that mediates entry of herpes simplex virus into the cell. Rev Med Virol (2007) 1.75
The pro-fusion domain of herpes simplex virus glycoprotein D (gD) interacts with the gD N terminus and is displaced by soluble forms of viral receptors. Proc Natl Acad Sci U S A (2005) 1.73
A cytomegaloviral protein reveals a dual role for STAT2 in IFN-{gamma} signaling and antiviral responses. J Exp Med (2005) 1.68
Case definition for progressive multifocal leukoencephalopathy following treatment with monoclonal antibodies. J Neurol Neurosurg Psychiatry (2012) 1.66
Early clinical experiences with the new influenza A (H1N1/09). Dtsch Arztebl Int (2009) 1.65
A heptad repeat in herpes simplex virus 1 gH, located downstream of the alpha-helix with attributes of a fusion peptide, is critical for virus entry and fusion. J Virol (2005) 1.62
NK cell activation through the NKG2D ligand MULT-1 is selectively prevented by the glycoprotein encoded by mouse cytomegalovirus gene m145. J Exp Med (2005) 1.60
Hepatitis C virus mutation affects proteasomal epitope processing. J Clin Invest (2004) 1.58
Expansion of protective CD8+ T-cell responses driven by recombinant cytomegaloviruses. J Virol (2004) 1.55
Prominent role of the Ig-like V domain in trans-interactions of nectins. Nectin3 and nectin 4 bind to the predicted C-C'-C"-D beta-strands of the nectin1 V domain. J Biol Chem (2002) 1.54
Entry of herpes simplex virus mediated by chimeric forms of nectin1 retargeted to endosomes or to lipid rafts occurs through acidic endosomes. J Virol (2004) 1.47
Herpes simplex virus gD forms distinct complexes with fusion executors gB and gH/gL in part through the C-terminal profusion domain. J Biol Chem (2009) 1.45
NKp46 and DNAM-1 NK-cell receptors drive the response to human cytomegalovirus-infected myeloid dendritic cells overcoming viral immune evasion strategies. Blood (2010) 1.38
Intracellular trafficking and maturation of herpes simplex virus type 1 gB and virus egress require functional biogenesis of multivesicular bodies. J Virol (2007) 1.33
Heptad repeat 2 in herpes simplex virus 1 gH interacts with heptad repeat 1 and is critical for virus entry and fusion. J Virol (2006) 1.29
The herpesviral Fc receptor fcr-1 down-regulates the NKG2D ligands MULT-1 and H60. J Exp Med (2006) 1.27
Herpes simplex virus glycoprotein K, but not its syncytial allele, inhibits cell-cell fusion mediated by the four fusogenic glycoproteins, gD, gB, gH, and gL. J Virol (2003) 1.26
Cross talk among the glycoproteins involved in herpes simplex virus entry and fusion: the interaction between gB and gH/gL does not necessarily require gD. J Virol (2009) 1.26
The domains of glycoprotein D required to block apoptosis induced by herpes simplex virus 1 are largely distinct from those involved in cell-cell fusion and binding to nectin1. J Virol (2003) 1.25
Rapid replacement of endemic measles virus genotypes. J Gen Virol (2002) 1.25
Hydrophobic alpha-helices 1 and 2 of herpes simplex virus gH interact with lipids, and their mimetic peptides enhance virus infection and fusion. J Virol (2006) 1.22
Selective down-regulation of the NKG2D ligand H60 by mouse cytomegalovirus m155 glycoprotein. J Virol (2005) 1.21
Human cytomegalovirus interferes with signal transducer and activator of transcription (STAT) 2 protein stability and tyrosine phosphorylation. J Gen Virol (2008) 1.19
{alpha}V{beta}3-integrin routes herpes simplex virus to an entry pathway dependent on cholesterol-rich lipid rafts and dynamin2. Proc Natl Acad Sci U S A (2010) 1.18
The cytomegaloviral protein pUL138 acts as potentiator of tumor necrosis factor (TNF) receptor 1 surface density to enhance ULb'-encoded modulation of TNF-α signaling. J Virol (2011) 1.17
IL-12-producing monocytes and HLA-E control HCMV-driven NKG2C+ NK cell expansion. J Clin Invest (2014) 1.17
Herpes simplex virus glycoproteins gH/gL and gB bind Toll-like receptor 2, and soluble gH/gL is sufficient to activate NF-κB. J Virol (2012) 1.16
Inhibition of human tumor growth in mice by an oncolytic herpes simplex virus designed to target solely HER-2-positive cells. Proc Natl Acad Sci U S A (2009) 1.14
Herpes simplex virus glycoproteins H/L bind to cells independently of {alpha}V{beta}3 integrin and inhibit virus entry, and their constitutive expression restricts infection. J Virol (2010) 1.13
Laboratory investigations are indispensable to monitor the progress of measles elimination--results of the German Measles Sentinel 1999-2003. J Clin Virol (2004) 1.11
Modulation of NKp30- and NKp46-mediated natural killer cell responses by poxviral hemagglutinin. PLoS Pathog (2011) 1.11
Probing neutralizing-antibody responses against emerging measles viruses (MVs): immune selection of MV by H protein-specific antibodies? J Gen Virol (2005) 1.06
The dynamics of mouse cytomegalovirus-specific CD4 T cell responses during acute and latent infection. J Immunol (2008) 1.03
A herpes simplex virus recombinant that exhibits a single-chain antibody to HER2/neu enters cells through the mammary tumor receptor, independently of the gD receptors. J Virol (2006) 1.02
Absence of cross-presenting cells in the salivary gland and viral immune evasion confine cytomegalovirus immune control to effector CD4 T cells. PLoS Pathog (2011) 1.00
Critical residues in the CC' ridge of the human nectin1 receptor V domain enable herpes simplex virus entry into the cell and act synergistically with the downstream region. Virology (2002) 0.99
A cytomegalovirus inhibitor of gamma interferon signaling controls immunoproteasome induction. J Virol (2004) 0.99
CD34+ progenitor cells mobilized by natalizumab are not a relevant reservoir for JC virus. Mult Scler (2010) 0.98
Substitution in the murine nectin1 receptor of a single conserved amino acid at a position distal from the herpes simplex virus gD binding site confers high-affinity binding to gD. J Virol (2002) 0.98
The herpes simplex virus JMP mutant enters receptor-negative J cells through a novel pathway independent of the known receptors nectin1, HveA, and nectin2. J Virol (2004) 0.97
The egress of herpesviruses from cells: the unanswered questions. J Virol (2006) 0.97
αVβ3-integrin relocalizes nectin1 and routes herpes simplex virus to lipid rafts. J Virol (2011) 0.96
Nonstructural 3/4A protease of hepatitis C virus activates epithelial growth factor-induced signal transduction by cleavage of the T-cell protein tyrosine phosphatase. Hepatology (2009) 0.95
Retracted The herpesvirus glycoproteins B and H.L are sequentially recruited to the receptor-bound gD to effect membrane fusion at virus entry. Proc Natl Acad Sci U S A (2006) 0.95
c-Src is required for complex formation between the hepatitis C virus-encoded proteins NS5A and NS5B: a prerequisite for replication. Hepatology (2011) 0.94
Replication-competent herpes simplex virus retargeted to HER2 as therapy for high-grade glioma. Mol Ther (2012) 0.93
αvβ3-integrin is a major sensor and activator of innate immunity to herpes simplex virus-1. Proc Natl Acad Sci U S A (2012) 0.92
"Activated" STAT proteins: a paradoxical consequence of inhibited JAK-STAT signaling in cytomegalovirus-infected cells. J Immunol (2013) 0.92
Vaccination against infection in patients with multiple sclerosis. Nat Rev Neurol (2012) 0.91
Identification of DNA-damage DNA-binding protein 1 as a conditional essential factor for cytomegalovirus replication in interferon-γ-stimulated cells. PLoS Pathog (2011) 0.90
Gamma interferon-induced interferon regulatory factor 1-dependent antiviral response inhibits vaccinia virus replication in mouse but not human fibroblasts. J Virol (2009) 0.90
The human cytomegalovirus Fc receptor gp68 binds the Fc CH2-CH3 interface of immunoglobulin G. J Virol (2008) 0.90
Classical and non-classical MHC I molecule manipulation by human cytomegalovirus: so many targets—but how many arrows in the quiver? Cell Mol Immunol (2014) 0.90
Inhibition of mouse TAP by immune evasion molecules encoded by non-murine herpesviruses. Mol Immunol (2011) 0.89
Preclinical therapy of disseminated HER-2⁺ ovarian and breast carcinomas with a HER-2-retargeted oncolytic herpesvirus. PLoS Pathog (2013) 0.89
The role of multiplex PCR in respiratory tract infections in children. Dtsch Arztebl Int (2014) 0.87
The crucial role of molecular diagnostics. Dtsch Arztebl Int (2014) 0.87
Physical and functional interactions of the cytomegalovirus US6 glycoprotein with the transporter associated with antigen processing. J Biol Chem (2005) 0.87
Mouse cytomegalovirus inhibits beta interferon (IFN-beta) gene expression and controls activation pathways of the IFN-beta enhanceosome. J Gen Virol (2008) 0.86
Human cytomegalovirus disrupts the major histocompatibility complex class I peptide-loading complex and inhibits tapasin gene transcription. J Virol (2011) 0.86
Type I interferon and NF-κB activation elicited by herpes simplex virus gH/gL via αvβ3 integrin in epithelial and neuronal cell lines. J Virol (2013) 0.85
Cell contact-dependent priming and Fc interaction with CD32+ immune cells contribute to the TGN1412-triggered cytokine response. J Immunol (2014) 0.85
Overcoming drug-resistant herpes simplex virus (HSV) infection by a humanized antibody. Proc Natl Acad Sci U S A (2013) 0.85
Herpesviral Fcgamma receptors: culprits attenuating antiviral IgG? Int Immunopharmacol (2004) 0.84
CMV-encoded Fcγ receptors: modulators at the interface of innate and adaptive immunity. Semin Immunopathol (2014) 0.84
The human cytomegalovirus-specific UL1 gene encodes a late-phase glycoprotein incorporated in the virion envelope. J Virol (2012) 0.82
The human cytomegalovirus glycoprotein UL16 traffics through the plasma membrane and the nuclear envelope. Cell Microbiol (2006) 0.82
Oncolytic herpes virus retargeted to HER-2. Cell Cycle (2009) 0.80
HCMV glycoprotein US6 mediated inhibition of TAP does not affect HLA-E dependent protection of K-562 cells from NK cell lysis. Hum Immunol (2003) 0.80
A natural tapasin isoform lacking exon 3 modifies peptide loading complex function. Eur J Immunol (2013) 0.80
Glycoprotein D of bovine herpesvirus 5 (BoHV-5) confers an extended host range to BoHV-1 but does not contribute to invasion of the brain. J Virol (2010) 0.79
The herpesvirus glycoproteins B and H.L are sequentially recruited to the receptor-bound gD to effect membrane fusion at virus entry. Proc Natl Acad Sci U S A (2007) 0.79
A novel assay for detecting virus-specific antibodies triggering activation of Fcγ receptors. J Immunol Methods (2012) 0.79
Cytomegalovirus immune evasion of myeloid lineage cells. Med Microbiol Immunol (2015) 0.78
The molecular basis of herpesviruses as oncolytic agents. Curr Pharm Biotechnol (2012) 0.77
Checks and balances between human cytomegalovirus replication and indoleamine-2,3-dioxygenase. J Gen Virol (2013) 0.77
Exploitation of herpesviral transactivation allows quantitative reporter gene-based assessment of virus entry and neutralization. PLoS One (2011) 0.77
High genotypic diversity and a novel variant of human cytomegalovirus revealed by combined UL33/UL55 genotyping with broad-range PCR. Virol J (2009) 0.77
Genetic analysis and antigenic characterization of human respiratory syncytial virus group A viruses isolated in Germany 1996-2008. Virus Genes (2013) 0.76
Interplay between CMVs and interferon signaling: implications for pathogenesis and therapeutic intervention. Future Microbiol (2012) 0.76
[University medical education in transition]. Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz (2009) 0.76
Updates and achievements in virology. Expert Rev Vaccines (2010) 0.75
Noncontrolled trial of monovalent AS03A-adjuvanted vaccine for 2009 pandemic influenza A(H1N1) in long-term dialysis patients and transplant recipients. Am J Kidney Dis (2011) 0.75
RAIDD Mediates TLR3 and IRF7 Driven Type I Interferon Production. Cell Physiol Biochem (2016) 0.75